Table 1 Clinical characteristics of type 1 diabetic patients before and after insulin and AHSCT treatments
From: Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus
| Â | Insulin-only group | AHSCT group | ||
|---|---|---|---|---|
Insulin-0M | Insulin-12M | AHSCT-0M | AHSCT-12M | |
Age (years) | 20.18 ± 4.02 | 18.86 ± 1.46 | ||
Gender (female/male) | 6/4 | 5/3 | ||
BMI (kg/cm2) | 18.28 ± 1.39 | 19.25 ± 1.11 | ||
FBG (mmol/L) | 6.50 ± 2.01 | 6.04 ± 1.70 | 6.26 ± 0.67 | 5.59 ± 1.40 |
HbA1c (%) (mmol/mol)a | 12.20 ± 3.50 (109.90 ± 38.42) | 7.33 ± 1.42++ (56.63 ± 15.45) | 11.49 ± 1.46 (102.00 ± 16.06) | 6.80 ± 0.60### (51.00 ± 6.73) |
Anti-GAD (units/ml) | 1230.38 (669.43–1957.29) | 1200.00 (725.41–1980.02) | 943.68 (294.69–2085.04) | 150.4* (31.83–1315.52) |
Insulin dose (U/kg/day) | 0.66 ± 0.30 | 0.52 ± 0.34 | 0.61 ± 0.27 | 0.15 ± 0.15**### |
Fasting C-peptide (ng/ml) | 0.62 ± 0.25 | 0.60 ± 0.50 | 0.71 ± 0.30 | 1.01 ± 0.23*# |
AUCC | 4.56 ± 2.50 | 4.76 ± 1.42 | 5.93 ± 2.54 | 9.59 ± 2.98**# |